FindTrial
Sign In

Evaluation of the Efficacy of 131I Therapy for Thyroid Follicular Carcinoma

Multicenter Retrospective Study on the Efficacy Evaluation of 131I Therapy for Thyroid Follicular Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107262
Enrollment
Unknown
Registered
2025-08-07
Start date
2025-08-15
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular thyroid carcinoma (FTC)

Interventions

Distant metastasis group :NA
Non-distant metastasis group:NA

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Underwent total/near-total thyroidectomy; 2.Postoperative pathology confirmed follicular thyroid carcinoma (FTC); 3.Received at least one course of ¹³¹I therapy; 4.Complete follow-up data for >6 months after initial ¹³¹I treatment;

Exclusion criteria

Exclusion criteria: 1.Patients with other incurable malignancies; 2.Any medical condition or circumstance deemed by investigators to potentially affect trial participation;

Design outcomes

Primary

MeasureTime frame
Therapy response;—

Countries

China

Contacts

Public ContactGao Zairong

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

gaobonn@hust.edu.cn+86 27 85726923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026